Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

The Efficacy of Repeat Talc Pleurodesis After Initial Failure
Wireko, F.W. , Ahmed, Adil , JAIMES, GABRIEL E ORTIZ, Mullon, John J., Midthun, David E. , Anderson, D.K., SCHIAVO, DANTE N, Edell, Eric S. , ORTIZ-JAIMES, GABRIEL E, Nelson, David R. , Kern, Ryan

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4082-A4082

10.1164/ajrccm.2025.211.abstracts.a4082 Get It

Abstract Rational: Talc pleurodesis is an effective intervention for preventing recurrent pleural effusions and pneumothoraces, particularly in non-surgical candidates. Due to its efficacy and safety, it is recommended as the most effective sclerosant for pleurodesis. However, in some cases, the initial pleurodesis fails, necessitating a repeat procedure. The efficacy of repeat talc pleurodesis after an initial failure is an area that requires further exploration. This study explores the safety and efficacy of repeat talc pleurodesis among patients who did not respond to the initial intervention. Methods: This retrospective study analyzed hospitalized patients who underwent 4g talc slurry pleurodesis from 2019 to 2024, focusing on demographics, comorbidities, initial pleurodesis failure, and recurrence rates. Pleurodesis failure was identified by lung sliding, recurrent effusion, or pneumothorax during the same hospitalization. The primary outcome was recurrence post-discharge, assessed by pleural effusion or pneumothorax within 180 days post-repeat pleurodesis. Results: This study included 94 patients (52.1% male, 47.9% female) with a mean age of 67.6. Among them, 79 (84%) received a single 4g dose of talc, while 15 (16%) received multiple 4g talc doses for initial pleurodesis. Recurrence occurred in 20 (25.3%) of the single-dose group and 1 (6.7%) of the multiple-dose group within 180 days, though the difference was not statistically significant (p=0.112). Recurrence-free rates were 93.6% at 30 days, 85.1% at 90 days, and 77.7% at 180 days. Of the 20 patients with recurrence after a single 4g dose of talc, 8 (40%) underwent repeat pleurodesis, with only one recurrence requiring surgical intervention. Additionally, there was no recurrence after repeat talc pleurodesis in the one patient with recurrence after receiving multiple 4g talc doses for initial pleurodesis. No associations were found between recurrence rates and factors like gender (p=0.213) or comorbidities (emphysema, COPD, lung malignancy). Chest pain was a common complaint, but no cases of respiratory distress were reported post-pleurodesis. Conclusion: The efficacy of initial talc pleurodesis (77.7%-93.6%) in this cohort aligns with existing literature. Multiple-dose talc pleurodesis effectively prevented recurrence in 93.3% of patients, with no reported respiratory distress. Additionally, repeat talc pleurodesis was successful in 87.5% of those with recurrence after an initial single 4g dose. These findings support multiple-dose talc pleurodesis and repeat talc pleurodesis as safe and effective options for preventing recurrence post-initial failure and post-repeat talc pleurodesis, respectively. Although no significant recurrence predictors were identified, future research could focus on patient-specific factors to enhance treatment selection and optimize outcomes.
Finding the Best Fit: A Head-To-Head Comparison of Triple Therapy Regimens in COPD
Versha, Fnu, Lohana, Abhichand, Patel, Viral , Iribarren, JL, LOHANA, ABHI , Chander, Subhash , Iribarren, J.B.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4032-A4032

10.1164/ajrccm.2025.211.abstracts.a4032 Get It

Abstract Introduction: Chronic obstructive pulmonary disease (COPD) represents a significant global health challenge, particularly in its moderate to severe cases, where effective management is crucial to improving patient outcomes. The integration of inhaled corticosteroids with long-acting β2-adrenoceptor agonists and long-acting muscarinic antagonists in fixed-dose combinations has emerged as a cornerstone of therapy. This study evaluates the efficacy of two triple therapy regimens — Glycopyrrolate, Budesonide, and Formoterol Fumarate (GLY/BUD/FOR) and Fluticasone Furoate, Vilanterol, and Umeclidinium (FF/VI/UMEC) —in adults aged 45 and older with diagnosed COPD with FEV1/FVC < 70% to assess the impact of these regimens on the preventing COPD exacerbations and acute hypoxemic respiratory failure. Methods: A retrospective cohort analysis was conducted using the TriNetX database. Patients with moderate to severe COPD and FEV1/FVC < 70% were identified based on ICD codes, and two cohorts were formed based on the prescribed inhaler therapy: GLY/BUD/FOR and FF/VI/UMEC. Patients with comorbid asthma, heart failure, or pneumonia were excluded. A 1:1 propensity-score matching (PSM) analysis was performed to balance covariates such as age, gender, smoking status, and baseline lung function to minimize confounding and bias. Post-matching, both had 16,052 patients. Ultimately, 23,331 patients (FF/VI/UMEC: 11,234, GLY/BUD/FOR: 12,097) with a mean age of 67.4 ± 10.1 years and 55.3% males were included. Results: Among groups, 10.4% of patients on FF/VI/UMEC experienced COPD exacerbations compared to 6.7% on GLY/BUD/FOR (Risk Ratio: 1.55, 95% CI: 1.42-1.69, p < 0.001). Kaplan-Meier analysis showed a lower survival probability in the FF/VI/UMEC group (77.7% vs. 83.9%, p < 0.001). For acute respiratory failure, 3.5% of patients on FF/VI/UMEC experienced this outcome compared to 2.8% on GLY/BUD/FOR (Risk Ratio: 1.28, 95% CI: 1.12-1.45, p = 0.003). Conclusion: Our study suggests that FF/VI/UMEC demonstrated an increased risk of COPD exacerbations and acute hypoxic respiratory failure compared to the group receiving GLY/BUD/FOR. This indicates that GLY/BUD/FOR may provide enhanced protective benefits in patients with moderate to severe COPD, improving disease management and minimizing healthcare resource utilization. Further studies are warranted to explore the long-term benefits and potential mechanisms underlying the observed differences.
Tragic Transformations and Differentiation Syndrome
Serafim, L. Piccolo, Moraes, Alice Gallo de

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3969-A3969

10.1164/ajrccm.2025.211.abstracts.a3969 Get It

Abstract Introduction: Differentiation syndrome (DS) is a life-threatening adverse drug reaction caused by differentiating agents, including all-trans retinoic acid, arsenic trioxide, inhibitors of mutant isocitrate dehydrogenase (e.g., enasidenib), and the FLT3 inhibitor gilteritinib. The proliferation of differentiated leukemic cells can alter cytokine balance, leading to tissue inflammation, but the pathogenesis remains incompletely understood. We present a case of severe DS in a patient with AML and multi-organ failure. Case: An 80-year-old female with a history of polycythemia vera and newly diagnosed AML, on decitabine, venetoclax, and enasidenib. She was admitted after her first treatment cycle with weakness, altered mental status, and neutropenic fever. Enasidenib was discontinued due to suspected DS, and she was treated with dexamethasone for five days. Three days after discontinuing steroids, her respiratory and mental status deteriorated, leading to a rapid response call and transfer to the ICU for acute hypoxemic respiratory failure. Point of care ultrasound revealed underfilled ventricles and collapsible IVC on inhalation. She became hypotensive and unresponsive, requiring intubation. Initial P/F was 72. PV tool with recruitment showed no low inflexion point but recruitable lung. Laboratory results revealed a WBC of 68.7 x 10⁹/L with 89% blasts which was increased from prior days and acute liver injury with hyperbilirubinemia. A CT scan revealed bilateral consolidations and pleural effusions with interlobular septal thickening. Despite initial oxygenation improvement with prone positioning, she remained hypotensive requiring norepinephrine, vasopressin, angiotensin II, and hydrocortisone. Methylene blue was administered with a favorable response. Leukocytosis worsened, and decitabine and hydroxyurea were initiated due to concern for uncontrolled acute leukemia. She was started on continuous renal replacement therapy (CRRT) for oliguric renal failure. After the fourth dose of decitabine, her shock resolved, urinary output improved, and leukocytosis decreased. However, in the following days, her oxygen requirements escalated, WBC again increased to 120 x 10⁹/L with 80% blasts, and she became hypotensive with signs of myocardial ischemia. She was ultimately transitioned to comfort care. Discussion: This case highlights severe DS following enasidenib administration, which progressed to multi-organ failure. Prompt initiation of systemic glucocorticoids is critical in the management of DS, and this condition should be considered in patients receiving active treatment for acute leukemia who require ICU-level care. Risk factors for DS development and the role of prophylaxis remain areas requiring further research in the context of acute leukemia treatment.
Triple M Concerns in the Critical Care Setting
Lorang, I.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3961-A3961

10.1164/ajrccm.2025.211.abstracts.a3961 Get It

Abstract Background The emergence of immune checkpoint inhibitors (ICI) has changed the landscape of cancer treatment; however, they can cause a variety of side effects. One serious complication is Triple M syndrome, which is a triad of ICI toxicities including myositis, myocarditis, and myasthenia gravis. Little literature regarding pathophysiology and guideline directed treatment exists, but case reports estimate a significant mortality rate of 60%. ICIs that have been recognized are pembrolizumab, nivolumab, and avelumab and ICI use in combination increases the risk of the syndrome. Current treatment regimens consist of steroids, immune modulators, and pyridostigmine. Ultimately, the syndrome requires rapid recognition and treatment to reduce mortality outcomes. Patient Case A 62 y.o. male with metastatic hepatocellular on atezolizumab/bevacizumab presented with a couple day history of progressive proximal upper and lower extremity weakness, mild dysarthria and dysphonia and shortness of breath. His head imaging was negative for acute stroke, but work-up revealed an AST of 1600, ALT of 500, total bilirubin of 9.1 and a CK of 9000. Troponin was also elevated at 273. There was immediate concern for Triple M syndrome given clinical and laboratory evidence of myositis and myocarditis. Therefore, the patient was transferred to the ICU and started on high-dose steroids. Myositis was confirmed via EMG and MRI of the left thigh showing intramuscular inflammation. EMG didn't show evidence of neuromuscular junction abnormalities and myasthenia antibodies were negative. Regarding myocarditis, with troponin elevation, TTE showed a hyperdynamic left ventricle and cardiac MRI displayed focal enhancement of the inferior septum consistent with mild myocarditis. Given worsening liver function and clinical status, IVIG was initiated. Unfortunately, the patient continued to decline and ultimately passed away after transitioning to comfort care.Discussion While this case did not clearly present a diagnosis of Triple M syndrome, two of the three triad were present, and the patient also had evidence of hepatitis, which has been seen with the syndrome. As seen in this case, there is a significant mortality rate, which emphasizes the importance to increase the awareness of Triple M syndrome in patients on ICIs. It also highlights our gap in knowledge regarding pathophysiology, standard diagnostic criteria and targeted treatments. Further research to understand which diagnostic markers are most sensitive and specific would help with early recognition but also inform treatment options. Mortality in Triple M remains high but with further understanding we may be able to counter this severe ICI toxicity.
Fulminant Cerebral Edema From Hyperammonemia in Alpha-1-antitrypsin Deficiency Related Cirrhosis and Adynamic Ileus After Gastrointestinal Bleeding
Al-Asaad, Abdullah , Rigby, Mark , Bhatt, S., Bauer, Philippe R.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3885-A3885

10.1164/ajrccm.2025.211.abstracts.a3885 Get It

Abstract Background Intracranial hypertension from cerebral edema is a feared complication in patients with acute liver failure. Diagnosing cerebral edema in critically ill patients can be challenging as it may be insidious in onset. We present a case of fulminant hyperammonemia-induced cerebral edema in a patient with newly diagnosed alpha-1-antitrypsin deficiency (A1AD) in the setting of intestinal ileus and ineffective lactulose therapy. Case A 48-year-old male with newly diagnosed A1AD-related cirrhosis, alcohol use, and obesity (BMI 48.9) presented at an outside facility with altered mental status. Physical exam showed waxing and waning mentation, and serum ammonia was 245 mcmol/L. Upon transfer to our facility, hemoglobin was 10.3 g/dL, creatinine 1.77 mg/dL, total bilirubin 1.5 mg/dL, INR 1.2, ALT 60 U/L, AST 107 U/L, ALP 173 U/L, and serum ammonia 138 mcmol/L. Serum alpha-1-antitrypsin returned at 41 mg/dL with SZ phenotype. Abdominal ultrasound showed cirrhosis with moderate ascites. Paracentesis demonstrated no acute peritonitis. After initiation of lactulose and rifaximin, his mental status improved initially. However, he experienced 2 episodes of coffee-ground emesis with hemoglobin dropping to 7.0 g/dL requiring blood transfusions. Urgent esophagogastroduodenoscopy, limited by large residual contents, found no active bleed. A nasogastric tube was placed. CT abdomen pelvis showed diffuse colonic and small bowel dilation consistent with adynamic ileus impairing lactulose administration. His mental status worsened, necessitating ICU transfer and intubation for airway protection. Serum ammonia peaked at 397 mcmol/L. Neostigmine did not restore any effective bowel movement, and continuous renal replacement therapy was initiated to control the hyperammonemia. A convulsive episode prompted imaging. Head CT showed diffuse cerebral edema, later confirmed on MRI (Figure 1). Continuous electroencephalogram showed diffuse slowing without epileptiform discharges. His protracted hospital course was marked by minimal neurological recovery requiring tracheostomy and ongoing supportive measures per family wishes. Discussion Cerebral edema is one of the leading causes of morbidity and mortality in patients with severe hyperammonemia, which can result in irreversible cortical and deep grey matter injury that typically spares perirolandic and medial occipital regions. Although the exact mechanism continues to be researched elevated serum ammonia plays a critical role in disrupting the innate cerebral autoregulation. Prompt diagnosis and early intracranial pressure control (head of the bed elevation, hyperventilation, mannitol, hypertonic saline) are paramount. Typical hyperammonemia treatment includes lactulose, rifaximin, or polyethylene glycol, and correction of any precipitating factors. Dialysis should be considered early to prevent cerebral toxicity in hyperammonemia refractory to conventional treatments.
Immune-related Myasthenia-Myocarditis-Myositis (Triple-M) Syndrome: ICU Cohort Study
Manjappachar, Nirmala, Karakuş, İbrahim Serhat , Heise, Kathrin, Nates, Joseph L. , Egan, Aoife M. , Moraes, Alice Gallo de , Niven, Alexander S.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3809-A3809

10.1164/ajrccm.2025.211.abstracts.a3809 Get It

Abstract Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. They are also associated with life-threatening immune-related adverse events (irAEs), including the rare, poorly understood, and potentially fatal triad of myasthenia gravis, myocarditis, and myositis(triple M syndrome). We aimed to describe the management, intensive care unit (ICU)utilization, and outcomes of patients with irAEs with a specific focus on triple M syndrome. Methods: We conducted a retrospective chart review of patients with irAEs admitted to three quaternary care hospitals between December 2018 and 2023. We aimed to collect data on demographics, cancer type, treatment, ICU resource utilization, and outcomes including mortality. Results: Over this 5-year period, 140 patients were admitted for irAEs. Forty-nine percent were male, median age was 73 (IQR 64-80) years, 7% were of African American or Asian descent, and 32%required ICU admission. Median ICU and hospital length of stay (LOS) were 1.5 (IQR 0.7-2.9)and 7.2 (IQR 4.1-13.4) days, respectively. Among ICU patients, 14/140 (10%) had myositis,22/140 (16%) myocarditis, and 9/140 (6.4%) myasthenia gravis. Triple-M syndrome was diagnosed in 7/140 (5%) patients, including 3 with metastatic melanoma, 2 with genitourinary malignancies, 1 with metastatic lung and 1 with colon cancer. Four had received pembrolizumab and 3 nivolumab. Median ICU and hospital LOS were 3 (IQR 1-6) and 10 (IQR 8-21) days in this group. Three patients required mechanical ventilation, one required tracheostomy, and one required vasopressor support. Triple-M management included corticosteroids, IVIG, pyridostigmine, mycophenolate mofetil, and rituximab. Patients with triple-M syndrome were significantly older than other patients with ICI toxicity (P <0.009) and had higher mortality (57%vs 25%, p = 0.07). Patients discharged from the ICU had a median survival of 67 (IQR 26-201)days. Conclusions: Patients with irAEs frequently require ICU level of support with significant morbidity and mortality, especially with triple M syndrome. Clinicians should always consider the possibility of triple-M syndrome in patients with multiple irAEs as symptoms can be subtle and easily overlooked. Corticosteroids remain the primary treatment of irAEs and can be combined with other immunosuppressive agents such as infliximab, anti-thymocyte globulin, or pyridostigmine. Unfortunately, mortality due to triple-M syndrome remains high underscoring the importance of early recognition and prompt multidisciplinary management of these toxicities.
Characteristics and Predictors of Critical Care Related Outcomes in Transplant Associated Hemophagocytic Lymphohistiocytosis
Viggiano, M., Li, Shifang , Skolnik, Avy A. , Sen, Ayan , Skolnik, A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3807-A3807

10.1164/ajrccm.2025.211.abstracts.a3807 Get It

Abstract Introduction:Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by excessive immune activation and cytokine release, leading to multi-organ failure and mortality. Despite guideline management to include chemotherapy and transplantation, the characteristics and predictors of critical outcomes in post-transplant-associated hemophagocytic lymphohistiocytosis (PT-HLH) remain poorly understood. Methods:This study is a retrospective cohort analysis of patients admitted to acute care hospitals in the U.S. with HLH between 2016 and 2018. We utilized the National Inpatient Sample, identifying HLH patients using International Classification of Diseases, Tenth Revision-Clinical Modification (ICD-10-CM) codes D76.1, D76.2, and D76.3. Patient demographics, such as age, gender, race, ethnicity, zip code, and insurance status, were obtained from the NIS, while hospital-level characteristics, location and teaching vs. non-teaching status, were considered in the study amongst others. We examined the baseline epidemiology of transplant status, including ICU-related outcomes and resource utilization in patients with and without transplants. Data were analyzed using STATA weighted function, with logistic regression for categorical outcomes. Results:Out of 8,330 adult HLH hospitalizations, 520 (6.2%) were transplant recipients. Among these, 350 (67%) had bone marrow transplants, 90 (17%) had kidney transplants, and 30 (5.8%) had liver transplants. The mean age of HLH patients was 50 ± 19 years; transplant patients were younger (mean age 46 ± 17 years) compared to non-transplant patients (50 ± 18 years), p<0.05. Transplant patients were more likely to be male (72.1% vs. 50.1%, p<0.05), have CMV infection (14.4% vs. 4.1%, p<0.05), be Hispanic (20.8% vs. 14.7%, p<0.05), come from higher median household income areas (38.8% vs. 24.5%, p<0.05), and be treated in teaching hospitals (96.1% vs. 85.8%, p<0.05). Among HLH patients who died in the hospital, 130 (25%) were transplant recipients, compared to 1,180 (15.1%) non-transplant recipients, p<0.05. After adjusting for potential confounders, transplant status was associated with a higher risk of mortality (adjusted odds ratio 1.77, 95% CI 1.11-2.83) and sepsis (adjusted odds ratio o1.78, 95% CI 1.08-2.92). Discussion:In examining a national cohort of PT-HLH cases, our findings review potential risk factors for critical care-related outcomes in post-transplant associated HLH care. PT-HLH patients in our cohort presented with distinct characteristics compared to non-transplant HLH cases. ICU-related outcomes showed statistically significant differences between transplant and non-transplant HLH patients. Specifically, transplant status remained independently associated with a higher risk of mortality and sepsis. Our findings underscore the importance of tailoring treatment plans to each patient's specific risk profile.
Retrospective Review of the Impact of Glucagon-like Peptide 1 Agonists on Gastrointestinal Motility and Outcomes in the Medical ICU
AHMAD, SUMERA R, Gmehlin, Cameron G. , Nemet, Marko , Gajic, Ognjen , Tekin, Aysun

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3800-A3800

10.1164/ajrccm.2025.211.abstracts.a3800 Get It

Abstract RATIONALE: Critical illness has been shown to disrupt gastrointestinal function, and patients admitted to the intensive care unit (ICU) often experience constipation, aspiration, ileus, and small bowel obstruction. Glucagon-like peptide 1 receptor agonists (GLP-1RA) have become increasingly prevalent in the treatment of type 2 diabetes mellitus and obesity. Pharmacovigilance studies suggest that use of GLP-1RAs may be associated with increased risk of clinically significant gastrointestinal effects. In this study, we assessed whether pre-ICU use of GLP-1RA for either diabetes or obesity was associated with adverse gastrointestinal outcomes. METHODS: This was a retrospective matched cohort study of patients with underlying obesity or diabetes admitted to a Mayo Clinic Medical ICU from 9/1/2018-12/31/2023. Patients who started GLP-1RA within <30 days or stopped them >30 days before admission were excluded. Out of 33,104 eligible patients, we identified 1,549 GLP-1RA exposed patients and matched these to three controls each based on age (±10), sex, body mass index (±5), presence of obesity, diabetes and complications, comorbidities associated with decreased motility, smoking status, alcoholism, abdominal surgeries, Apache score (±20), and Charlson comorbidity index (CCI). Development of gastrointestinal dysfunction (determined by ICD codes) and hospital- and ICU- free days were the outcomes. Conditional logistic regression and mixed linear models were used for the analyses. RESULTS: The final, matched cohort included 6,196 patients. Most patients were male (56.3%), the median age was 66 years (IQR 58-74), 69.9% had a diagnosis of obesity, and 97.5% had a diagnosis of diabetes. Of the patients, 22.9% had a history of abdominal surgery during their lifetime and 30% had surgery within 30 days of admission. When comparing GLP-1RA exposed and non-exposed patients, significant differences were noted in use of motility altering medications (p=0.001, OR 6.75, CI 2.11-21.56), BMI (p<0.001, estimate=0.6, CI 0.47-0.72), and APACHE score (p<0.001, estimate=14.75, CI14.45 – 15.06). Univariable analysis showed that rates of constipation, impaction, and nausea/vomiting were significantly higher among GLP-1RA exposed patients admitted to the ICU, while rates of obstruction were significantly lower (Table 1). After adjusting for APACHE score, only nausea/vomiting remained statistically significant. After controlling for APACHE, GLP-1RA use was associated with an increased number of hospital free days (Table 1). CONCLUSIONS: Our research suggests that in the medical ICU population, GLP-1RA use is unlikely to be associated with adverse GI outcomes. Furthermore, GLP-1RA may be associated with overall hospital length of stay but not ICU length of stay.
The Effects of Hyperchloremia on the Duration of Mechanical Ventilation in Critically Ill Patients
Wireko, F.W. , Heise, Katherine J., Oeckler, Richard A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3792-A3792

10.1164/ajrccm.2025.211.abstracts.a3792 Get It

Abstract Rationale Hyperchloremia, characterized by elevated chloride levels (>110 mEq/L) in the blood, frequently occurs in critically ill patients following aggressive fluid resuscitation with chloride-rich solutions. It is associated with metabolic acidosis, leading to negative clinical outcomes such as higher morbidity and mortality. However, the impact of hyperchloremia on the duration of mechanical ventilation remains unclear. This study evaluates the correlation between hyperchloremia and the duration of mechanical ventilation in critically ill patients. Methods A retrospective analysis was conducted on intensive care unit patients admitted between 2018 and 2023 who required mechanical ventilation. Patients were categorized into hyperchloremic (serum chloride >110 mEq/L) and non-hyperchloremic groups. The hyperchloremic group was further subdivided into those with metabolic acidosis (pH <7.35) and those without acidosis (pH >7.35). The primary outcome measured was the duration of mechanical ventilation across these groups. Results The study included 7,333 patients, 408 in the hyperchloremic group and 6,926 in the non-hyperchloremic group. Patients with hyperchloremia experienced significantly longer ventilation durations, with an average of 5.9 days compared to 2.6 days in the non-hyperchloremic group (p < 0.01). Among the hyperchloremic subgroups, those with metabolic acidosis had a mean ventilation duration of 4.9 days compared to 6.2 days in those without acidosis (p = 0.7), suggesting no apparent significant influence of acid-base status on ventilation duration. Discussion The study found that hyperchloremia correlates with longer ventilation duration (4.9-6.2 days vs. 2.6 days), independent of pH. While metabolic acidosis might impair respiratory function and increase ventilatory needs, evidence is mixed. Hyperchloremic metabolic acidosis can alter respiratory regulation, causing issues like tachypnea, ventilator dyssynchrony, and the need for sedation, complicating weaning from ventilation. However, hyperchloremia does not always impair respiratory muscle function. The study is limited by its retrospective nature, making causal conclusions difficult. However, the study suggests that better electrolyte management may reduce ventilation duration and improve patient outcomes. Conclusion This study demonstrates a significant association between hyperchloremia and prolonged mechanical ventilation, independent of pH status. The findings suggest that hyperchloremia may either be a marker of severe illness or aggressive resuscitation and directly contribute to prolonged ventilatory support. These findings offer hope for improved patient outcomes, as they suggest that chloride management strategies, including chloride-sparing resuscitation, could potentially reduce mechanical ventilation duration in critically ill patients.
An Analysis of Lactate Measurement Patterns in Critical Care-Evidence or Intuition?
Amal, T., Nath, R., Bhattacharyya, A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3730-A3730

10.1164/ajrccm.2025.211.abstracts.a3730 Get It

Abstract Introduction: Lactate measurement trends have increased over the last few decades. A study by Chanu et. Al), showed an increase in lactate measurements from 11% (2003) to 48% (2013); associated with an increase in repeating lactate within the first 6 hours (during the “ebb” phase)- (23% to 69%). Despite this, lactate measurement has a low sensitivity (34%) and fails to detect around 35% of severe sepsis cases at onset. This may be explained by clinical reliance on certain prognostic scoring to purse lactate trends. Results: Patients who died had significantly higher measurement frequencies (mean 10.93 ± 12.72) compared to survivors (mean 6.63 ± 11.03). Logistic regression analysis revealed measurement frequency as an independent predictor of mortality (OR = 1.036, 95% CI: 1.031-1.041, p < 0.001), with each additional measurement associated with a 3.6% increase in mortality odds. Age was also significantly associated with mortality (OR = 1.019, 95% CI: 1.015-1.023, p < 0.001), while gender showed no significant effect (OR = 1.065, 95% CI: 0.955-1.187, p = 0.257). Analysis of racial/ethnic disparities revealed significant variations in measurement patterns, though most racial categories showed no independent association with mortality after controlling for other factors. Discussion: Our analysis showed increased testing frequency based on the SOFA score. This may be related to physician's cognitive bias based on the clinical presentation. Increased lactate measurement frequency was associated with increased mortality, which may relate to severity of disease. However it also highlights further investigation to determine if lactate measuring frequency affects outcome. Our analysis also showed age and gender affecting mortality, further pointing towards possible effect of health care inequir=ty and clinical bias